Actemra IL-6R Neutralisation Bioassays

Bioassays provide the means to directly assess the fundamental biological activity of Actemra/RoActemra (tocilizumab), and as such signify a key component of a product characterization study.  Our extensive experience in the development of bioassays for the assessment of a wide range of monoclonal antibody products has allowed us to develop cell-based assays to measure the blocking activity of Actemra/RoActemra and tocilizumab biosimilar products for use in clone selection, process development, characterization and similarity studies.  We offer assays that characterize both classical and trans mechanisms of signalling.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy